ABSTRACT
PURPOSE Bi-allelic TECPR2 variants have been associated with a complex syndrome with features of both a neurodevelopmental and neurodegenerative disorder. Here, we aim to provide a comprehensive clinical description and variant interpretation framework.
METHODS Through an international collaboration, we identified 13 individuals from 12 families with bi-allelic TECPR2-variants. We systemically reviewed clinical and molecular data of this cohort and 11 cases previously reported. Phenotypes were standardized using Human Phenotype Ontology terms.
RESULTS A cross-sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections and central/nocturnal hypopnea as core manifestations. A review of brain MRI scans demonstrated a thin corpus callosum in 59%. We evaluated 14 distinct variants. Missense variants in TECPR2 are predominantly located in the N- and C-terminal regions containing β-propeller repeats. Despite constituting nearly half of disease associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains difficult. We estimate a pathogenic variant carrier frequency of 1/1,221 in the general and 1/155 in the Jewish Ashkenazi population.
CONCLUSION Based on clinical, neuroimaging and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/treatment of individuals with TECPR2-associated disorder. This sets the stage for future prospective natural history studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
B.B. is supported by scholarships from the German National Academic Foundation and the Carl Duisberg Program by the Bayer Foundation. B.P. is supported by the Deutsche Forschungsgemeinschaft (DFG) through grant PO2366/2 1. D.E-F. is supported by grants from the CureAP4 Foundation, CureSPG50 Foundation, Spastic Paraplegia Foundation, the Thrasher Research Fund, and a joint research agreement with Astellas Pharmaceutical Inc. and MitoBridge Inc..
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study adheres to the principles set out in the Declaration of Helsinki. The following Research Ethics Committee approved genetic testing in research setting within the study: Ethical Committee of the Medical Faculty, Leipzig University (P1), Institutional Review Board at Boston Childrens Hospital (IRB-P00033016, P2, P4 and P5), Ethics Review Board of Technical University of Munich (P3), Institutional Review Board of King Faisal Specialist Hospital and Research Center (KFSRHC RAC# 2080006 and 2121053, P7, P8 and P13). Genetic testing for P6, P9, P10, P11 and P12 was performed in diagnostic setting. The authors received and archived written consent of the legal guardians to publish genetic and clinical data (P1 - P13) as well as photographs, CT scan and MRI images (P1, P4 and P6).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICTS OF INTEREST All authors involved in the study declare no conflicts of interest relevant to this study.
Data Availability
All data generated or analyzed during this study can be found in the supplementary materials provided.
ABBREVIATIONS
- AA
- amino acid
- ACMG
- American College of Medical Genetics and Genomics
- CNS
- central nervous system
- DNA
- deoxyribonucleic acid
- EEG
- electroencephalogram
- HSP
- hereditary spastic paraplegia
- Mb
- mega base
- MRI
- magnetic resonance imaging
- NDD
- neurodevelopmental disorder
- NMD
- nonsense-mediated mRNA decay
- qPCR
- quantitative polymerase chain reaction
- RNA
- ribonucleic acid
- ROH
- runs of homozygosity
- SD
- standard deviation
